{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:14:55Z","timestamp":1792440895596,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n \n Internal dosimetry in radiopharmaceutical therapy (RPT) traditionally prioritizes methodological optimization driven by physical dose accuracy. However, even recommended multiple-time-point (MTP) dosimetry remains subject to uncertainties related to limited sampling schedules, pharmacokinetic, and curve-fitting modeling assumptions. In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [\n 177<\/jats:sup>\n Lu]Lu-PSMA-617 RPT, we explored an outcome-driven dosimetry optimization strategy by comparing MTP and single-time-point (STP) dosimetry, and identifying optimal time-points (TPs) for H\u00e4nscheid approximation based on therapy outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Clinical and image data from 50 patients were retrospectively analyzed. Transient treatment-emergent adverse events (TEAEs) and prostate-specific antigen (PSA) response were monitored following CTCAE v5.0 and PCWG3. Cycle-level mean absorbed doses (\n MTPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n , and\n 1d-<\/jats:italic>\n ,\n 2d-<\/jats:italic>\n ,\n 3d-STPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n based on single SPECT acquisitions at 1-, 2-, 3-day(s) p.i.) were computed for organs-at-risk and whole-body tumors. Additionally, cumulative absorbed doses (\n STPD<\/jats:italic>\n \n cum<\/jats:italic>\n <\/jats:sub>\n &\n MTPD<\/jats:italic>\n \n cum<\/jats:italic>\n <\/jats:sub>\n ) were derived for whole-body tumors.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Bone marrow STP dosimetry correlated significantly with anaemia grading (\n 1d-STPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n : Spearman\u2019s \u03c1=0.35;\n 2d-STPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n : Spearman\u2019s \u03c1=0.41;\n 3d-STPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n : Spearman\u2019s \u03c1=0.46; all\n p<\/jats:italic>\n \n adj<\/jats:italic>\n <\/jats:sub>\n <0.001), aligning with\n MTPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n (Spearman\u2019s \u03c1=0.43,\n p<\/jats:italic>\n <0.001). Williams\u2019\n F<\/jats:italic>\n -test confirmed no significant difference in correlation strength between\n STPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n &\n MTPD<\/jats:italic>\n \n tox<\/jats:italic>\n <\/jats:sub>\n derived correlations at any TPs. For PSA response, both\n MTPD<\/jats:italic>\n \n cum<\/jats:italic>\n <\/jats:sub>\n (Spearman\u2019s \u03c1=-0.26,\n p<\/jats:italic>\n \n adj<\/jats:italic>\n <\/jats:sub>\n <0.05) and\n STPD<\/jats:italic>\n \n cum<\/jats:italic>\n <\/jats:sub>\n (\n 1d-<\/jats:italic>\n &\n 2d-STPD<\/jats:italic>\n \n cum<\/jats:italic>\n <\/jats:sub>\n : Spearman\u2019s \u03c1=-0.34,\n p<\/jats:italic>\n \n adj<\/jats:italic>\n <\/jats:sub>\n <0.001) showed significant correlations, without statistically significant differences between\n STPD<\/jats:italic>\n \n cum<\/jats:italic>\n <\/jats:sub>\n &\n MTPD<\/jats:italic>\n \n cum<\/jats:italic>\n <\/jats:sub>\n derived correlations.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The outcome-driven TP selection for H\u00e4nscheid-based STP dosimetry converges with the physics-based choice within 2-day p.i., the clinically driven approach offers an alternative and complementary strategy for dosimetry development and may facilitate its translation into clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00259-026-07936-w","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:40:20Z","timestamp":1781332820000},"page":"6461-6472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcome-driven dosimetry optimization for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-4727","authenticated-orcid":false,"given":"Jiaxi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Vinicius","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warissara","family":"Jutidamrongphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Amon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Ormieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"11","key":"7936_CR1","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1088\/0031-9155\/58\/11\/3631","volume":"58","author":"L Cheng","year":"2013","unstructured":"Cheng L, Hobbs RF, Segars PW, Sgouros G, Frey EC. Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters. Phys Med Biol. 2013;58(11):3631\u201347. https:\/\/doi.org\/10.1088\/0031-9155\/58\/11\/3631.","journal-title":"Phys Med Biol"},{"issue":"1","key":"7936_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-017-0201-8","volume":"5","author":"T Ryden","year":"2018","unstructured":"Ryden T, Heydorn Lagerlof J, Hemmingsson J, Marin I, Svensson J, Bath M, et al. Fast GPU-based Monte Carlo code for SPECT\/CT reconstructions generates improved (177)Lu images. EJNMMI Phys. 2018;5(1):1. https:\/\/doi.org\/10.1186\/s40658-017-0201-8.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"7936_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-019-0268-5","volume":"6","author":"SMB Peters","year":"2019","unstructured":"Peters SMB, van der Werf NR, Segbers M, van Velden FHP, Wierts R, Blokland K, et al. Towards standardization of absolute SPECT\/CT quantification: a multi-center and multi-vendor phantom study. EJNMMI Phys. 2019;6(1):29. https:\/\/doi.org\/10.1186\/s40658-019-0268-5.","journal-title":"EJNMMI Phys"},{"issue":"4","key":"7936_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.zemedi.2018.12.001","volume":"29","author":"A Rinscheid","year":"2019","unstructured":"Rinscheid A, Lee J, Kletting P, Beer AJ, Glatting G. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy. Z Med Phys. 2019;29(4):314\u201325. https:\/\/doi.org\/10.1016\/j.zemedi.2018.12.001.","journal-title":"Z Med Phys"},{"issue":"7","key":"7936_CR5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","volume":"61","author":"PA Jackson","year":"2020","unstructured":"Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in (177)Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61(7):1030\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.233411.","journal-title":"J Nucl Med"},{"issue":"1","key":"7936_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.zemedi.2022.06.004","volume":"33","author":"D Hardiansyah","year":"2023","unstructured":"Hardiansyah D, Riana A, Beer AJ, Glatting G. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model. Z Med Phys. 2023;33(1):70\u201381. https:\/\/doi.org\/10.1016\/j.zemedi.2022.06.004.","journal-title":"Z Med Phys"},{"issue":"2","key":"7936_CR7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1118\/1.4906242","volume":"42","author":"EC Ao","year":"2015","unstructured":"Ao EC, Wu NY, Wang SJ, Song N, Mok GS. Improved dosimetry for targeted radionuclide therapy using nonrigid registration on sequential SPECT images. Med Phys. 2015;42(2):1060\u201370. https:\/\/doi.org\/10.1118\/1.4906242.","journal-title":"Med Phys"},{"issue":"1","key":"7936_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.21037\/qims.2019.10.09","volume":"10","author":"T Li","year":"2020","unstructured":"Li T, Zhu L, Lu Z, Song N, Lin KH, Mok GSP. BIGDOSE: software for 3D personalized targeted radionuclide therapy dosimetry. Quant Imaging Med Surg. 2020;10(1):160\u201370. https:\/\/doi.org\/10.21037\/qims.2019.10.09.","journal-title":"Quant Imaging Med Surg"},{"issue":"2","key":"7936_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2967\/jnumed.112.105825","volume":"54","author":"A Dieudonne","year":"2013","unstructured":"Dieudonne A, Hobbs RF, Lebtahi R, Maurel F, Baechler S, Wahl RL, et al. Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. J Nucl Med. 2013;54(2):236\u201343. https:\/\/doi.org\/10.2967\/jnumed.112.105825.","journal-title":"J Nucl Med"},{"issue":"3","key":"7936_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00259-020-05013-4","volume":"48","author":"A Akhavanallaf","year":"2021","unstructured":"Akhavanallaf A, Shiri I, Arabi H, Zaidi H. Whole-body voxel-based internal dosimetry using deep learning. Eur J Nucl Med Mol Imaging. 2021;48(3):670\u201382. https:\/\/doi.org\/10.1007\/s00259-020-05013-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7936_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s13139-022-00769-z","volume":"57","author":"KM Kim","year":"2023","unstructured":"Kim KM, Lee MS, Suh MS, Cheon GJ, Lee JS. Voxel-based internal dosimetry for (177)Lu-labeled radiopharmaceutical therapy using deep residual learning. Nucl Med Mol Imaging. 2023;57(2):94\u2013102. https:\/\/doi.org\/10.1007\/s13139-022-00769-z.","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"7936_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-020-05038-9","volume":"48","author":"M Konijnenberg","year":"2021","unstructured":"Konijnenberg M, Herrmann K, Kobe C, Verburg F, Hindorf C, Hustinx R, et al. EANM position paper on article 56 of the council directive 2013\/59\/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021;48(1):67\u201372. https:\/\/doi.org\/10.1007\/s00259-020-05038-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"7936_CR13","doi-asserted-by":"publisher","first-page":"97S","DOI":"10.2967\/jnumed.116.186841","volume":"58","author":"U Eberlein","year":"2017","unstructured":"Eberlein U, Cremonesi M, Lassmann M. Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med. 2017;58(Suppl 2):97S-103S. https:\/\/doi.org\/10.2967\/jnumed.116.186841.","journal-title":"J Nucl Med"},{"key":"7936_CR14","unstructured":"Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S-61S. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10025848."},{"issue":"3","key":"7936_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2967\/jnumed.116.178483","volume":"58","author":"S Okamoto","year":"2017","unstructured":"Okamoto S, Thieme A, Allmann J, D\u2019Alessandria C, Maurer T, Retz M, et al. Radiation Dosimetry for (177)Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. J Nucl Med. 2017;58(3):445\u201350. https:\/\/doi.org\/10.2967\/jnumed.116.178483.","journal-title":"J Nucl Med"},{"issue":"1","key":"7936_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2967\/jnumed.118.210377","volume":"60","author":"P Kletting","year":"2019","unstructured":"Kletting P, Thieme A, Eberhardt N, Rinscheid A, D\u2019Alessandria C, Allmann J, et al. Modeling and predicting tumor response in radioligand therapy. J Nucl Med. 2019;60(1):65\u201370. https:\/\/doi.org\/10.2967\/jnumed.118.210377.","journal-title":"J Nucl Med"},{"issue":"11","key":"7936_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1080\/09553002.2024.2404448","volume":"100","author":"M Kazemi-Jahromi","year":"2024","unstructured":"Kazemi-Jahromi M, Yazdani E, Karamzade-Ziarati N, Asadi M, Sadeghi M, Geramifar P. Personalized dosimetry assessment of [(177)Lu]Lu-PSMA-617 radioligand therapy in the management of Metastatic Castration-Resistant Prostate Cancer. Int J Radiat Biol. 2024;100(11):1551\u20139. https:\/\/doi.org\/10.1080\/09553002.2024.2404448.","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"7936_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","volume":"52","author":"P Jackson","year":"2022","unstructured":"Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation dosimetry in (177)Lu-PSMA-617 therapy. Semin Nucl Med. 2022;52(2):243\u201354. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.11.003.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"7936_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-01007-z","volume":"13","author":"AB Peterson","year":"2023","unstructured":"Peterson AB, Mirando DM, Dewaraja YK. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for (177)Lu-DOTATATE PRRT in patients and clinically realistic simulations. EJNMMI Res. 2023;13(1):57. https:\/\/doi.org\/10.1186\/s13550-023-01007-z.","journal-title":"EJNMMI Res"},{"issue":"5","key":"7936_CR20","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/mp.12886","volume":"45","author":"MT Madsen","year":"2018","unstructured":"Madsen MT, Menda Y, O\u2019Dorisio TM, O\u2019Dorisio MS. Technical note: single time point dose estimate for exponential clearance. Med Phys. 2018;45(5):2318\u201324. https:\/\/doi.org\/10.1002\/mp.12886.","journal-title":"Med Phys"},{"issue":"1","key":"7936_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H Hanscheid","year":"2018","unstructured":"Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with (177)Lu-DOTATATE\/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75\u201381. https:\/\/doi.org\/10.2967\/jnumed.117.193706.","journal-title":"J Nucl Med"},{"issue":"9","key":"7936_CR22","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2967\/jnumed.122.264770","volume":"64","author":"M Straub","year":"2023","unstructured":"Straub M, Kupferschlager J, Serna Higuita LM, Weissinger M, Dittmann H, la Fougere C, et al. Dual-time-point posttherapy (177)Lu-PSMA-617 SPECT\/CT describes the uptake kinetics of mCRPC lesions and prognosticates patients\u2019 outcome. J Nucl Med. 2023;64(9):1431\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264770.","journal-title":"J Nucl Med"},{"issue":"5","key":"7936_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2967\/jnumed.122.264594","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, Delker A, Volter F, Unterrainer LM, Kaiser L, Bartenstein P, et al. Toward single-time-point image-based dosimetry of (177)Lu-PSMA-617 therapy. J Nucl Med. 2023;64(5):767\u201374. https:\/\/doi.org\/10.2967\/jnumed.122.264594.","journal-title":"J Nucl Med"},{"issue":"1","key":"7936_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-024-00636-0","volume":"11","author":"D Grob","year":"2024","unstructured":"Grob D, Prive BM, Muselaers CHJ, Mehra N, Nagarajah J, Konijnenberg MW, et al. Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT\/CT. EJNMMI Phys. 2024;11(1):34. https:\/\/doi.org\/10.1186\/s40658-024-00636-0.","journal-title":"EJNMMI Phys"},{"key":"7936_CR25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266871","author":"S Resch","year":"2024","unstructured":"Resch S, Ziegler SI, Sheikh G, Unterrainer LM, Zacherl MJ, Bartenstein P, et al. Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [(177)Lu]Lu-PSMA-I&T Therapy. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.123.266871.","journal-title":"J Nucl Med."},{"key":"7936_CR26","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.123.267067","author":"YH Kao","year":"2024","unstructured":"Kao YH, Falzone N, Pearson M, Sivaratnam D. First-strike rapid predictive dosimetry and dose response for (177)Lu-PSMA therapy in metastatic castration-resistant prostate cancer. J Nucl Med Technol. 2024. https:\/\/doi.org\/10.2967\/jnmt.123.267067.","journal-title":"J Nucl Med Technol"},{"key":"7936_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2024.111378","volume":"210","author":"E Yazdani","year":"2024","unstructured":"Yazdani E, Asadi M, Geramifar P, Karamzade-Ziarati N, Vosoughi H, Kazemi-Jahromi M, et al. A step toward simplified dosimetry of radiopharmaceutical therapy via SPECT frame duration reduction. Appl Radiat Isot. 2024;210:111378. https:\/\/doi.org\/10.1016\/j.apradiso.2024.111378.","journal-title":"Appl Radiat Isot"},{"key":"7936_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100792","volume":"47","author":"C Jiang","year":"2024","unstructured":"Jiang C, Ji T, Qiao Q. Application and progress of artificial intelligence in radiation therapy dose prediction. Clin Transl Radiat Oncol. 2024;47:100792. https:\/\/doi.org\/10.1016\/j.ctro.2024.100792.","journal-title":"Clin Transl Radiat Oncol"},{"key":"7936_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06737-3","author":"S Xue","year":"2024","unstructured":"Xue S, Gafita A, Zhao Y, Mercolli L, Cheng F, Rauscher I, et al. Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06737-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7936_CR30","doi-asserted-by":"publisher","unstructured":"Kurth J, Heuschkel M, Tonn A, Schildt A, Hakenberg OW, Krause BJ, et al. Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer. Cancers (Basel). 2021;13(15)https:\/\/doi.org\/10.3390\/cancers13153884.","DOI":"10.3390\/cancers13153884"},{"issue":"1","key":"7936_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-020-00339-2","volume":"7","author":"M Sandstrom","year":"2020","unstructured":"Sandstrom M, Freedman N, Fross-Baron K, Kahn T, Sundin A. Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Phys. 2020;7(1):73. https:\/\/doi.org\/10.1186\/s40658-020-00339-2.","journal-title":"EJNMMI Phys"},{"issue":"7","key":"7936_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.120.254656","volume":"62","author":"X Hou","year":"2021","unstructured":"Hou X, Brosch J, Uribe C, Desy A, Boning G, Beauregard JM, et al. Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies. J Nucl Med. 2021;62(7):1006\u201311. https:\/\/doi.org\/10.2967\/jnumed.120.254656.","journal-title":"J Nucl Med."},{"issue":"4","key":"7936_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nucl Med"},{"key":"7936_CR34","doi-asserted-by":"publisher","unstructured":"Volter F, Mittlmeier L, Gosewisch A, Brosch-Lenz J, Gildehaus FJ, Zacherl MJ, et al. Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after (177)Lu-PSMA-617 Radioligand Therapy. Diagnostics (Basel). 2021;11(3)https:\/\/doi.org\/10.3390\/diagnostics11030428.","DOI":"10.3390\/diagnostics11030428"},{"issue":"4","key":"7936_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.remnie.2021.05.005","volume":"41","author":"S Zarehparvar Moghadam","year":"2022","unstructured":"Zarehparvar Moghadam S, Askari E, Divband G, Shakeri S, Aryana K. Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with (177)Lu-PSMA-617: a single center study. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022;41(4):239\u201346. https:\/\/doi.org\/10.1016\/j.remnie.2021.05.005.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"issue":"3","key":"7936_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","volume":"45","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, et al. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45(3):496\u2013508. https:\/\/doi.org\/10.1007\/s00259-017-3895-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7936_CR37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597\u2013610. https:\/\/doi.org\/10.1016\/S1470-2045(23)00158-4.","journal-title":"Lancet Oncol"},{"issue":"12","key":"7936_CR38","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"10276","key":"7936_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"issue":"2","key":"7936_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.remnie.2021.12.005","volume":"42","author":"ON Sever","year":"2023","unstructured":"Sever ON, Elboga U, Sahin E, Cayirli YB, Yesil Cinkir H. (177)Lu-PSMA-617 RLT in mCRPC: a single center experience, the earlier could be the better. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2023;42(2):71\u20136. https:\/\/doi.org\/10.1016\/j.remnie.2021.12.005.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"7936_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07010-3","author":"J Hu","year":"2024","unstructured":"Hu J, Seifert R, Karkampouna S, Gomes CV, Xue S, Afshar-Ormieh A, et al. Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-07010-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7936_CR42","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.230024","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal J, Breit HC, Meyer MT, Pradella M, Hinck D, Sauter AW, et al. TotalSegmentator: robust segmentation of 104 anatomic structures in CT images. Radiol Artif Intell. 2023;5(5):e230024. https:\/\/doi.org\/10.1148\/ryai.230024.","journal-title":"Radiol Artif Intell"},{"issue":"12","key":"7936_CR43","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Schafers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61(12):1786\u201392. https:\/\/doi.org\/10.2967\/jnumed.120.242057.","journal-title":"J Nucl Med"},{"issue":"16","key":"7936_CR44","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125.","journal-title":"Cancer Res"},{"issue":"3","key":"7936_CR45","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.cmpb.2009.09.002","volume":"98","author":"M Modat","year":"2010","unstructured":"Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, et al. Fast free-form deformation using graphics processing units. Comput Methods Programs Biomed. 2010;98(3):278\u201384. https:\/\/doi.org\/10.1016\/j.cmpb.2009.09.002.","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"7936_CR46","doi-asserted-by":"publisher","first-page":"024003","DOI":"10.1177\/1.JMI.1.2.024003","volume":"1","author":"M Modat","year":"2014","unstructured":"Modat M, Cash DM, Daga P, Winston GP, Duncan JS, Ourselin S. Global image registration using a symmetric block-matching approach. J Med Imaging (Bellingham). 2014;1(2):024003. https:\/\/doi.org\/10.1177\/1.JMI.1.2.024003.","journal-title":"J Med Imaging (Bellingham)"},{"key":"7936_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.12.004","author":"KN Chi","year":"2024","unstructured":"Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, et al. Safety analyses of the phase 3 VISION trial of [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.004.","journal-title":"Eur Urol"},{"key":"7936_CR48","unstructured":"Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) v5. 0. Cancer Ther Eval Progr. 2017;155. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf?utm_source=chatgpt.com"},{"issue":"7","key":"7936_CR49","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148\u201359. https:\/\/doi.org\/10.1200\/JCO.2007.12.4487.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7936_CR50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2307\/2983326","volume":"159","author":"DJ Hand","year":"1996","unstructured":"Hand DJ. Statistics and the theory of measurement. J Royal Statistical Soc: Series A (Statistics in Society). 1996;159(3):445\u201373.","journal-title":"J Royal Statistical Soc: Series A (Statistics in Society)"},{"issue":"1","key":"7936_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-00952-z","volume":"13","author":"SMB Peters","year":"2023","unstructured":"Peters SMB, Mink MCT, Prive BM, de Bakker M, de Lange F, Muselaers CHJ, et al. Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. EJNMMI Res. 2023;13(1):6. https:\/\/doi.org\/10.1186\/s13550-023-00952-z.","journal-title":"EJNMMI Res"},{"key":"7936_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1246881","volume":"10","author":"G Chen","year":"2023","unstructured":"Chen G, Lu Z, Jiang H, Afshar-Oromieh A, Rominger A, Shi K, et al. Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points. Front Med. 2023;10:1246881. https:\/\/doi.org\/10.3389\/fmed.2023.1246881.","journal-title":"Front Med"},{"issue":"12","key":"7936_CR53","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","volume":"48","author":"R Manafi-Farid","year":"2021","unstructured":"Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, Briganti A, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48(12):4028\u201341. https:\/\/doi.org\/10.1007\/s00259-021-05237-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7936_CR54","doi-asserted-by":"publisher","unstructured":"Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bogemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48(1):113-22. https:\/\/doi.org\/10.1007\/s00259-020-04797-9.","DOI":"10.1007\/s00259-020-04797-9"},{"issue":"4","key":"7936_CR55","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222010","volume":"307","author":"R Seifert","year":"2023","unstructured":"Seifert R, Rasul S, Seitzer K, Eveslage M, Rahbar Nikoukar L, Kessel K, et al. A prognostic risk score for prostate cancer based on PSMA PET-derived organ-specific tumor volumes. Radiology. 2023;307(4):e222010. https:\/\/doi.org\/10.1148\/radiol.222010.","journal-title":"Radiology"},{"key":"7936_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.zemedi.2023.01.007","author":"D Hardiansyah","year":"2023","unstructured":"Hardiansyah D, Riana A, Eiber M, Beer AJ, Glatting G. Population-based model selection for an accurate estimation of time-integrated activity using non-linear mixed-effects modelling. Z Med Phys. 2023. https:\/\/doi.org\/10.1016\/j.zemedi.2023.01.007.","journal-title":"Z Med Phys."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07936-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:46Z","timestamp":1787986846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07936-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7936"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07936-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Cantonal Research Ethics Committee of Bern (Ethical approval numbers: 2023-01877).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Financial and non-Financial interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Axel Rominger, Prof. Ali Afshar-Oromieh and Prof. Kuangyu Shi are editors of this journal.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}